title: Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma.
abstract: Esophageal cancer is one of the deadliest cancers, with a dismal prognosis. It is increasingly recognized that esophageal cancer is a heterogeneous disease. It can be subdivided into two distinct groups: squamous cell carcinoma and adenocarcinoma, based on histological appearance. In the Western world, the incidence of squamous cell carcinoma was considerably higher than esophageal adenocarcinoma (EA) until the 1990s when, due to a dramatic increase, the incidence of EA surpassed that of squamous cell carcinoma. EA typically follows a well-established stepwise evolution from chronic inflammation due to reflux esophagitis (RE) that progresses to metaplasia (Barrett's esophagus [BE]) to dysplasia, which often culminates in EA. The pathophysiology of EA is complex and involves diverse factors, including gastroesophageal reflux, gastric acid secretion, dysfunction of the antireflux barrier, gastric emptying disturbances, and abnormalities in esophageal defense mechanisms. The current understanding of the etiology of EA is mainly derived from epidemiological studies of risk factors such as cigarette smoking, obesity, gastroesophageal reflux disorders (GERD), and low fruit and vegetable consumption. Numerous studies have been done, but the factors that drive the dynamic increase in the incidence of EA remain elusive. The advent of widespread antibiotic use occurred in the 1950s, preceding the surge of EA. Based on this temporal sequence, it has been hypothesized that antibiotics alter the microbiome to which the esophagus is exposed in patients who have GERD and that chronic exposure to this abnormal microbiome (ie, changes in species diversity or abundance) accounts for the increase in EA. If changes in the proposed factors alter the stepwise progression (RE-BE-dysplasia-EA), they may represent potential targets for chemoprevention. New discoveries will help improve our understanding of the biology and pathogenesis of these cancers, and aid in finding novel therapeutic targets.
authors.affiliation: Department of Pathology, New York University School of Medicine, New York, NY, USA.
authors.forename: Antonio Galvao
authors.initials: AG
authors.lastname: Neto
authors.affiliation: Department of Pathology, New York University School of Medicine, New York, NY, USA.
authors.forename: April
authors.initials: A
authors.lastname: Whitaker
authors.affiliation: Department of Veterans Affairs New York Harbor Healthcare System, New York, NY, USA; Departments of Medicine and Pathology, New York University School of Medicine, New York, NY, USA. Electronic address: Zhiheng.pei@med.nyu.edu.
authors.forename: Zhiheng
authors.initials: Z
authors.lastname: Pei
mesh_terms: D000230:Adenocarcinoma / Q000382:microbiology / Q000517:prevention & control*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D063646:Carcinogenesis; D018890:Chemoprevention; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D004938:Esophageal Neoplasms / Q000382:microbiology / Q000517:prevention & control*; D005764:Gastroesophageal Reflux / Q000382:microbiology*; D000069196:Gastrointestinal Microbiome; D041981:Gastrointestinal Tract / Q000382:microbiology*; D006801:Humans; D064307:Microbiota; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents; D052246:Cyclooxygenase 2 Inhibitors; D016328:NF-kappa B; D052247:Nitric Oxide Synthase Type II
keywords: Chemoprevention; Esophageal adenocarcinoma; Innate immunity; Microbiome